AsiDNA

AsiDNA™ Letter – No. 2

AsiDNA™ Letter – No. 2 Role of AsiDNA™ in the new combination strategies Ladies, Gentlemen and shareholders The complexity and diversity of cancers require multiple therapeutic approaches. The combination of several anti-cancer agents has become the norm in oncology, especially to treat the very aggressive or resistant cancers. Thanks to its original anti-tumor activity and its good tolerance already clinically demonstrated, AsiDNA™ is…read more →

AsiDNA™ Letter – No. 1

Ladies, Gentlemen and Shareholders, The clinical development of AsiDNA™ is well on its way and we would like to inform you regularly about the progress being made through a Letter dedicated to this first-in-class candidate. In this first issue, we go back to the fundamentals of the DNA Damage Response (DDR) therapeutic approach in oncology, which consists of fighting cancer…read more →

Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors

Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced the intratumoral activation of its DNA-PK target, confirming its mechanism of action The full results of the study will be presented at upcoming international scientific meetings Paris (France), May 28, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris,…read more →

Abstract – Journal of Clinical Oncology

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy A reference paper on new approaches in the field of DDR, including AsiDNA™, and their interest in combination treatments Link to the article: https://ascopubs.org/doi/10.1200/JCO.18.02050

Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy

DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in patients with solid tumors eligible to such treatments Initial results are expected in the second half of 2019   Paris (France), Mai 6, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”),…read more →

Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting

Paris (France), March 25, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today provides details on the presentation of data from five studies supporting the…read more →

Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting

Paris (France), February 13, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced that results of five preclinical study supporting the differentiated profile of…read more →

Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor

Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical development of AsiDNA™ based on these predictive biomarkers of response   Paris (France), January 3, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development…read more →

Onxeo receives EPO Intent-to-Grant Notice for new patent protecting AsiDNA™ in combination with any PARP inhibitor

Combination patent to be granted in Europe until 2036   Paris (France), December 18, 2018 – 8.30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced having been notified by the European Patent Office…read more →

Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNA™, a First-In-Class DNA Damage Response Inhibitor

Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with no drug-related serious adverse event and no dose-limiting toxicity Company intends to expand AsiDNA™ clinical program in combination in targeted indications as soon as H1 2019 Company to host a conference call for analysts and investors today at 5.30 pm…read more →

Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019

Paris, October 18, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced that the Company was invited to present an overview of AsiDNA™ for the treatment of solid tumors at…read more →

Onxeo to Present at the 11th Edition of the “Rencontres de la Cancérologie Française” Oncology Conference

Paris, October 3, 2018 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced its participation in the 11th edition of the Rencontres de la Cancérologie Française (RCFr), a major event dedicated to innovation in…read more →